NRD
EWTX icon

Nebula Research & Development’s Edgewise Therapeutics EWTX Stock Holding History

Nebula Research & Development’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,219
Closed -$173K – 317
2025
Q2 		$173K Buy
+13,219
New +$191K 0.01% 901

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Nebula Research & Development's EWTX Position: Q3 2025 in Review

Nebula Research & Development sold out of Edgewise Therapeutics (EWTX) in Q3 2025, closing a stake of 13,219 shares — an estimated $173K sold.

Nebula Research & Development first reported a position in EWTX in Q2 2025 and held it in 1 quarter. The position peaked at $173K in Q2 2025. 173 funds tracked by Wall St. Rank hold EWTX as of Q3 2025.

  • Nebula Research & Development reported no remaining Edgewise Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 13,219 Edgewise Therapeutics shares in Q3 2025, an estimated $173K.
  • Nebula Research & Development first reported a position in Edgewise Therapeutics in Q2 2025 and held it in 1 quarter.
  • Nebula Research & Development's Edgewise Therapeutics position peaked at $173K in Q2 2025.
  • 173 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.